Pfizer
NEWS
In a weekend interview on CBS’ “Face the Nation,” Albert Bourla, chief executive officer of Pfizer indicated they may have key data from its Phase III trial of the vaccine to the U.S. Food and Drug Administration by the end of October.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
Preclinical data for Pfizer and BioNTech’s Phase II/III COVID-19 mRNA vaccine candidate generated BNT162b2 strong anti-viral effects against an infectious SARS-CoV-2 challenge.
The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Moderna, Novavax, Pfizer, Merck and Sanofi all signed the pledge promising to ensure that any vaccine put forth by one or more of the companies meets the rigorous standards for approval.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
The U.S. government has financially backed the development of six different vaccine candidates aimed at the novel coronavirus. Although billions of dollars have been appropriated to the pandemic, at least four of those potential preventative treatments are predicted to fail in the clinic.
It was a relatively quiet week for clinical trial news. Here’s a look.
Today’s data describes key safety and immunogenicity data from the U.S. Phase I study for BNT162b.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 21, 2020.
JOBS
IN THE PRESS